2024-01-28 04:07:55
Health experts have praised a potentially “groundbreaking” vaccine to treat bowel cancer in its early stages, as trials are scheduled to begin in England and Australia, according to a report published by the newspaper “Independent” British.
The treatment will be trialled at the Royal Surrey Institution of the National Health Service in England, and the Queen Elizabeth Hospital in Adelaide, Australia.
Doctors plan to give the vaccine to patients before performing surgical intervention to remove the tumor, hoping that the vaccination will support the immune system to respond in the event of a relapse and the cancer returns later.
With “simple” changes… How do you protect yourself from half of the cancers?
A doctor specializing in cancer tumors said that more than half of the cases of this disease can be prevented through “simple and sustainable changes.”
Dr. Tony Dillon, a consultant medical oncologist at the Royal Surrey Foundation, proposed the idea of the trial in cooperation with Professor Tim Price in Australia, where the two worked with a research team during the past four years to develop the vaccine.
Dillon said: “This is the first therapeutic vaccine for any cancer in the digestive system and we have high hopes that it will be very successful, and we believe that the tumor will completely disappear from the patient following this treatment.”
The trial will be managed by the Cancer Research UK Clinical Trials Unit at the University of Southampton in collaboration with the Royal Surrey and Queen Elizabeth Hospital.
There will be 10 patient enrollment sites, including six in Australia and four in the UK, with 44 patients enrolled in the study over 18 months.
The role of food in cancer prevention.. Is it real?
The “Al-Youm” program on Al-Hurra channel highlighted the role of food in fighting cancer in humans, especially with the emergence of studies indicating the benefits of some foods in this role.
Patients will undergo an endoscopy, then a sample of their tissue will be tested to see if they qualify for the trial, and if they are, they will receive three doses of the vaccine before surgery to remove the tumor.
The trial will be available to only 44 patients around the world, and following its completion, the vaccine will either be licensed for use, or a larger study will be conducted.
Dillon expressed his optimism by saying: “This will change their (patients’) lives because it means that they will likely not need to undergo surgery, and will be satisfied with the vaccine only.”
He continued, “The work we have done here at Royal Surrey is wonderful, and we are very proud to participate in this global trial, and we believe it might be the key to treating bowel cancer in the future.”
Bowel cancer, also known as colorectal cancer, is the third most common type of cancer, with an annual incidence worldwide of more than 1.2 million cases, and a mortality rate of regarding 50 percent.
1706420924
#surgery #Creating #pioneering #vaccine #bowel #cancer
